So low ... so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors

被引：35
作者：
Gencer, Baris [1 ]
Mach, Francois [1 ]
机构：
[1] Geneva Univ Hosp, Dept Specialties Med, Cardiol Div, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva 14, Switzerland
来源：
EUROPEAN HEART JOURNAL | 2018年 / 39卷 / 05期
基金：
瑞士国家科学基金会;
关键词：
COGNITIVE FUNCTION; FOURIER TRIAL; OLDER-ADULTS; CHOLESTEROL; EFFICACY; SAFETY; METAANALYSIS; EVOLOCUMAB; STATINS; DISEASE;
D O I：
10.1093/eurheartj/ehx742
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This editorial refers to 'No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: meta-analysis of individual patient data'+, by P.D. Harvey et al., on page 374.
引用
收藏
页码：382 / 384
页数：3
相关论文
共 16 条
  • [1] [Anonymous], 2017, CELL METAB, DOI [DOI 10.1016/j.cmet.2017.07.012, DOI 10.1136/BMJ.J1648]
  • [2] Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers Insights Derived From the FOURIER Trial
    Arrieta, Alejandro
    Hong, Jonathan C.
    Khera, Rohan
    Virani, Salim S.
    Krumholz, Harlan M.
    Nasir, Khurram
    [J]. JAMA CARDIOLOGY, 2017, 2 (12) : 1369 - 1374
  • [3] Risk factors for dementia diagnosis in German primary care practices
    Booker, Anke
    Jacob, Louis E. C.
    Rapp, Michael
    Bohlken, Jens
    Kostev, Karel
    [J]. INTERNATIONAL PSYCHOGERIATRICS, 2016, 28 (07) : 1059 - 1065
  • [4] Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041
  • [5] Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes
    Gencer, Baris
    Koskinas, Konstantinos C.
    Raber, Lorenz
    Karagiannis, Alexios
    Nanchen, David
    Auer, Reto
    Carballo, David
    Carballo, Sebastian
    Klingenberg, Roland
    Heg, Dik
    Matter, Christian M.
    Luscher, Thomas F.
    Rodondi, Nicolas
    Mach, Francois
    Windecker, Stephan
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (11):
  • [6] Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
    Giugliano, Robert P.
    Pedersen, Terje R.
    Park, Jeong-Gun
    De Ferrari, Gaetano M.
    Gaciong, Zbigniew A.
    Ceska, Richard
    Toth, Kalman
    Gouni-Berthold, Ioanna
    Lopez-Miranda, Jose
    Schiele, Francois
    Mach, Francois
    Ott, Brian R.
    Kanevsky, Estelle
    Pineda, Armando Lira
    Somaratne, Ransi
    Wasserman, Scott M.
    Keech, Anthony C.
    Sever, Peter S.
    Sabatine, Marc S.
    [J]. LANCET, 2017, 390 (10106) : 1962 - 1971
  • [7] Cognitive Function in a Randomized Trial of Evolocumab
    Giugliano, Robert P.
    Mach, Francois
    Zavitz, Kenton
    Kurtz, Christopher
    Im, Kyungah
    Kanevsky, Estella
    Schneider, Jingjing
    Wang, Huei
    Keech, Anthony
    Pedersen, Terje R.
    Sabatine, Marc S.
    Sever, Peter S.
    Robinson, Jennifer G.
    Honarpour, Narimon
    Wasserman, Scott M.
    Ott, Brian R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) : 633 - 643
  • [8] Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol A Prespecified Analysis of the IMPROVE-IT Trial
    Giugliano, Robert P.
    Wiviott, Stephen D.
    Blazing, Michael A.
    De Ferrari, Gaetano M.
    Park, Jeong-Gun
    Murphy, Sabina A.
    White, Jennifer A.
    Tershakovec, Andrew M.
    Cannon, Christopher P.
    Braunwald, Eugene
    [J]. JAMA CARDIOLOGY, 2017, 2 (05) : 547 - 555
  • [9] No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
    Harvey, Philip D.
    Sabbagh, Marwan N.
    Harrison, John E.
    Ginsberg, Henry N.
    Chapman, M. John
    Manvelian, Garen
    Moryusef, Angele
    Mandel, Jonas
    Farnier, Michel
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 (05) : 374 - +
  • [10] Cognitive Resilience to Apolipoprotein E ε4 Contributing Factors in Black and White Older Adults
    Kaup, Allison R.
    Nettiksimmons, Jasmine
    Harris, Tamara B.
    Sink, Kaycee M.
    Satterfield, Suzanne
    Metti, Andrea L.
    Ayonayon, Hilsa N.
    Yaffe, Kristine
    [J]. JAMA NEUROLOGY, 2015, 72 (03) : 340 - 348
12